NeuroMetrix Inc logo

NURO - NeuroMetrix Inc Share Price

$9 0.1  0.7%

Last Trade - 15/10/21

Micro Cap
Market Cap £36.8m
Enterprise Value £30.7m
Revenue £6.01m
Position in Universe 6055th / 7245
Unlock NURO Revenue
Relative Strength (%)
1m -14.8%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -76.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
7.30 12.0 17.1 16.1 9.27 7.38 22.3 26.7 +0.2%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2021, NeurometrixInc revenues increased 24% to $4.4M. Net loss decreased 61%to $591K. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Lower net loss reflects Research anddevelopment decrease of 27% to $875K (expense), Sales andmarketing decrease of 17% to $663K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


NURO Revenue Unlock NURO Revenue

Net Income

NURO Net Income Unlock NURO Revenue

Normalised EPS

NURO Normalised EPS Unlock NURO Revenue

PE Ratio Range

NURO PE Ratio Range Unlock NURO Revenue

Dividend Yield Range

NURO Dividend Yield Range Unlock NURO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NURO EPS Forecasts Unlock NURO Revenue
Profile Summary

NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated April 25, 2001
Public Since July 22, 2004
No. of Shareholders: 25
No. of Employees: 20
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 5,628,907
Free Float (0.0%)
Eligible for
NURO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for NURO
Upcoming Events for NURO
Thursday 21st October, 2021
Q3 2021 NeuroMetrix Inc Earnings Call
Thursday 21st October, 2021
Q3 2021 NeuroMetrix Inc Earnings Release
Wednesday 26th January, 2022 Estimate
Q4 2021 NeuroMetrix Inc Earnings Release
Frequently Asked Questions for NeuroMetrix Inc
What is the NeuroMetrix Inc share price?

As of 15/10/21, shares in NeuroMetrix Inc are trading at $9, giving the company a market capitalisation of £36.8m. This share price information is delayed by 15 minutes.

How has the NeuroMetrix Inc share price performed this year?

Shares in NeuroMetrix Inc are currently trading at $9 and the price has moved by 0.423k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the NeuroMetrix Inc price has moved by 0.317k% over the past year.

What are the analyst and broker recommendations for NeuroMetrix Inc?

Of the analysts with advisory recommendations for NeuroMetrix Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for NeuroMetrix Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will NeuroMetrix Inc next release its financial results?

NeuroMetrix Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the NeuroMetrix Inc dividend yield?

NeuroMetrix Inc does not currently pay a dividend.

Does NeuroMetrix Inc pay a dividend?

NeuroMetrix Inc does not currently pay a dividend.

When does NeuroMetrix Inc next pay dividends?

NeuroMetrix Inc does not currently pay a dividend.

How do I buy NeuroMetrix Inc shares?

To buy shares in NeuroMetrix Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of NeuroMetrix Inc?

Shares in NeuroMetrix Inc are currently trading at $9, giving the company a market capitalisation of £36.8m.

Where are NeuroMetrix Inc shares listed? Where are NeuroMetrix Inc shares listed?

Here are the trading details for NeuroMetrix Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: NURO
What kind of share is NeuroMetrix Inc?

Based on an overall assessment of its quality, value and momentum, NeuroMetrix Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a NeuroMetrix Inc share price forecast 2021?

Shares in NeuroMetrix Inc are currently priced at $9. At that level they are trading at 0.459% discount to the analyst consensus target price of 0.00.

Analysts covering NeuroMetrix Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.4 for the next financial year.

How can I tell whether the NeuroMetrix Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NeuroMetrix Inc. Over the past six months, the relative strength of its shares against the market has been 0.170k%. At the current price of $9, shares in NeuroMetrix Inc are trading at 43.26% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the NeuroMetrix Inc PE Ratio?

We were not able to find PE ratio data for NeuroMetrix Inc.

Who are the key directors of NeuroMetrix Inc?

NeuroMetrix Inc's management team is headed by:

Shai Gozani - CHM
David Goodman - IND
Thomas Higgins - CFO
Nancy Katz - IND
David Van Avermaete - IND
Who are the major shareholders of NeuroMetrix Inc?

Here are the top five shareholders of NeuroMetrix Inc based on the size of their shareholding:

Topline Capital Management, LLC Hedge Fund
Percentage owned: 10.13% (570k shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 2.66% (150k shares)
Vanguard Extended Market Index Fund Mutual Fund
Percentage owned: 1.18% (66.2k shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 1.18% (66.2k shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 0.81% (45.7k shares)
Similar to NURO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.